Cohance Lifesciences has informed that in continuation of communication dated August 13, 2025, September 18, 2025 and October 26, 2025 regarding the inspection conducted by the US Food and Drug Administration (USFDA) at the Company’s Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from August 4, 2025 to August 12, 2025 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), the Company has received a Warning Letter for the Company’s Nacharam formulation facility. The Company had earlier informed the Stock Exchanges that the facility was classified as Official Action Indicated (OAI), and the said Warning Letter is in continuation of the same.
The above information is a part of company’s filings submitted to BSE.
